Walethmade%252525252525252525252525252525252525252525252520bromide

# Walethmade bromide (Glycopyrrolate) ## Overview Walethmade bromide is an international proprietary name for **Glycopyrrolate**, a synthetic quaternary ammonium anticholinergic agent. Unlike atropine, it does not cross the blood-brain barrier significantly, resulting in fewer central nervous system side effects. ## Primary Indications * **Preoperative medication:** Reduction of salivary, tracheobronchial, and pharyngeal secretions. * **Intraoperative:** Reversal of muscarinic effects of cholinergic agents (e.g., neostigmine). * **Respiratory:** Management of chronic severe drooling (sialorrhea) in pediatric cerebral palsy or other neurologic conditions. * **Gastrointestinal:** Adjunctive therapy for peptic ulcer disease (less common). ## Adult Dosing * **Preoperative:** 0.004 mg/kg IM 30–60 minutes before induction. * **Intraoperative (Reversal of neuromuscular blockade):** 0.2 mg for every 1 mg of neostigmine or equivalent anticholinesterase. * **Peptic Ulcer:** 1 mg PO 3 times daily (up to 2 mg 3 times daily). ## Pediatric Dosing * **Preoperative:** 0.004–0.01 mg/kg IM/IV. * **Sialorrhea (Chronic):** Initial dose 0.02 mg/kg PO 3 times daily; titrate based on response and tolerance. Maximum recommended titration is usually 0.1 mg/kg or 1.5–3 mg per dose, though local protocols vary significantly. ## Dose Adjustments * **Renal Impairment:** Use with caution. Accumulation may occur in severe renal dysfunction; consider dose reduction or increased dosing intervals. * **Hepatic Impairment:** No specific guidelines; use caution. ## Contraindications * Hypersensitivity to glycopyrrolate. * Closed-angle glaucoma. * Obstructive uropathy (e.g., bladder neck obstruction). * Obstructive GI disease (e.g., pyloric stenosis, paralytic ileus). * Severe ulcerative colitis or toxic megacolon. * Myasthenia gravis (unless used to treat adverse effects of cholinergic therapy). ## Adverse Effects * **Common:** Xerostomia (dry mouth), constipation, urinary retention, blurred vision, tachycardia. * **Serious:** Heat prostration (decreased sweating), arrhythmias, confusion (rare), anaphylaxis. ## Key Drug Interactions * **Potentiation:** Increased anticholinergic effects when combined with antihistamines, tricyclic antidepressants, or antipsychotics. * **Absorption:** May decrease the rate/extent of absorption of other oral medications by slowing GI motility. * **Antimyasthenics:** May mask signs of overdosage of cholinergic agents. ## Monitoring * Monitor heart rate (tachycardia risk). * Monitor for signs of urinary retention. * Monitor bowel sounds/constipation, particularly in pediatric patients with neurological impairment. ## Clinical Pearls * Quaternary ammonium structure prevents CNS penetration, making it safer than atropine for patients prone to delirium. * In pediatric sialorrhea management, dosing must be carefully titrated to manage drooling without causing intolerable systemic anticholinergic toxicity. * Always confirm concentration before administration; errors between various strengths/formulations can be fatal. *** *Disclaimer: Clinical dosing and protocols vary by institution and patient-specific needs. Always verify dosages and indications against current, localized, and manufacturer-approved prescribing information before administration.*